Medicare Enrolled
Dr. Tyler Kang, M.D.
Hematology & Oncology · Walnut Creek, CA
Practice pattern: Clinical Cardiology
— Primarily office-based clinical cardiology
Low-engagement
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating.
This page presents federal public records about Dr. Kang from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Kang?
Request a correction or review of any data shown here. Provider portal →
What this data tells you about Dr. Kang
Dr. Tyler Kang is a hematology & oncology specialist in Walnut Creek, CA, with 18 years of NPI registration. Based on federal Medicare data, Dr. Kang performed 271 Medicare services across 221 unique beneficiaries.
Between the years covered by Open Payments, Dr. Kang received a total of $16,531 from 74 pharmaceutical and/or device companies across 501 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in hematology & oncology. Most payments are for meals and travel — low-value interactions common across virtually all practicing physicians. Patients may wish to discuss these relationships with their provider.
The Data Coverage level for Dr. Kang is Very High — reflecting how much public federal data is available about this provider. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.
✓ 18 years in practice
▲ 271 Medicare services
$16,531 industry payments
Medicare Practice Summary
Medicare Utilization ↗271
Medicare services
Bottom 23% in CA for hematology & oncology
Lower Medicare volume may reflect subspecialty focus, hospital-based work, or a higher share of non-Medicare patients.
221
Unique beneficiaries
$108
Avg. Medicare payment
Medicare patients only (65+ / disabled) · How to read this →
~15 Medicare services per year of practice
Top procedures by volume
Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.
| Procedure | Volume | Avg. paid | Avg. submitted |
|---|---|---|---|
| Office visit, established patient (30-39 min) A follow-up office visit for an existing patient lasting between 30 and 39 minutes. The visit involves medical evaluation and management of the patient's condition. |
128 | $90 | $233 |
| New patient office visit, complex (60-74 min) | 58 | $139 | $182 |
| Initial hospital admission, high complexity Initial hospital inpatient or observation care for a new patient involving high-level medical decision making, with at least 75 minutes total time on the date of the encounter. |
27 | $145 | $442 |
| Hospital follow-up visit, high complexity Subsequent hospital inpatient or observation care for an existing patient involving high-level medical decision making, with at least 50 minutes total time on the date of the encounter. |
25 | $101 | $228 |
| Office visit, established patient, complex (40-54 min) An office or outpatient visit for an existing patient lasting between 40 and 54 minutes. This level of service is determined by the total time spent on the date of the encounter. |
17 | $136 | $344 |
| Telephone medical discussion, 11-20 minutes A phone conversation with a physician lasting between 11 and 20 minutes. |
16 | $54 | $162 |
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
Industry Payment Transparency
Open Payments through 2024 ↗$16,531
Total received (2018-2024)
Avg $2,362/year across 7 years
Top 24% in CA for hematology & oncology
A higher payment rank reflects disclosed industry relationships (consulting, research, speaking) common among subspecialists — not wrongdoing.
74
Companies
501
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →
Payment profile
Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$10,381 (62.8%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$6,150 (37.2%)
Payment trend by year
Annual totals from pharmaceutical and medical device companies.
2024
$4,419
2023
$423
2022
$497
2021
$933
2020
$301
2019
$2,433
2018
$7,526
Payments by company (2024)
Consulting
Speaking
Meals & Travel
Research
E.R. Squibb & Sons, L.L.C.
$486
AstraZeneca Pharmaceuticals LP
$458
PFIZER INC.
$416
Merck Sharp & Dohme LLC
$384
Celgene Corporation
$287
Janssen Biotech, Inc.
$278
ABBVIE INC.
$242
Novartis Pharmaceuticals Corporation
$206
Takeda Pharmaceuticals U.S.A., Inc.
$113
Daiichi Sankyo Inc.
$104
SEAGEN INC.
$99
Astellas Pharma US Inc
$88
ARRAY BIOPHARMA INC
$88
Coherus Biosciences Inc.
$88
Eisai Inc.
$81
ADC Therapeutics America, Inc.
$81
Silk Road Medical, Inc.
$80
Lilly USA, LLC
$77
Gilead Sciences, Inc.
$64
Myriad Genetic Laboratories, Inc.
$62
Genentech USA, Inc.
$60
GENZYME CORPORATION
$58
Ipsen Biopharmaceuticals, Inc
$35
Genentech, Inc.
$33
Genmab U.S., Inc.
$33
Biocon Biologics Inc
$32
Bayer Healthcare Pharmaceuticals Inc.
$28
PUMA BIOTECHNOLOGY, INC.
$27
JAZZ PHARMACEUTICALS INC.
$27
PharmaEssentia USA Corporation
$27
Regeneron Healthcare Solutions, Inc.
$25
GlaxoSmithKline, LLC.
$25
Kyowa Kirin, Inc.
$25
TAIHO ONCOLOGY, INC.
$23
Novocure Inc.
$22
Mirati Therapeutics, Inc.
$22
Spectrum Pharmaceuticals Inc.
$22
SpringWorks Therapeutics, Inc.
$22
Sumitomo Pharma America, Inc.
$21
Incyte Corporation
$20
Azurity Pharmaceuticals, Inc.
$19
Kite Pharma, Inc.
$17
Karyopharm Therapeutics Inc.
$14
Top 3 companies account for 30.8% of 2024 payments
All-time payments by company (2018-2024) ›
E.R. Squibb & Sons, L.L.C.
$6,363
Novartis Pharmaceuticals Corporation
$813
AstraZeneca Pharmaceuticals LP
$806
PFIZER INC.
$777
Takeda Pharmaceuticals U.S.A., Inc.
$616
Janssen Biotech, Inc.
$607
Celgene Corporation
$555
Merck Sharp & Dohme LLC
$497
Astellas Pharma US Inc
$470
Daiichi Sankyo Inc.
$420
Lilly USA, LLC
$371
Merck Sharp & Dohme Corporation
$371
Genentech USA, Inc.
$330
ABBVIE INC.
$242
Novocure Inc.
$235
Bayer HealthCare Pharmaceuticals Inc.
$173
Gilead Sciences, Inc.
$160
PUMA BIOTECHNOLOGY, INC.
$151
Amgen Inc.
$122
Pharmacyclics LLC, An AbbVie Company
$120
Seagen Inc.
$112
Myriad Genetic Laboratories, Inc.
$108
AMAG Pharmaceuticals, Inc.
$103
Array BioPharma Inc.
$102
SEAGEN INC.
$99
Eisai Inc.
$98
ARRAY BIOPHARMA INC
$88
Coherus Biosciences Inc.
$88
ADC Therapeutics America, Inc.
$81
Silk Road Medical, Inc.
$80
GENZYME CORPORATION
$79
Medtronic, Inc.
$73
Boehringer Ingelheim Pharmaceuticals, Inc.
$67
EISAI INC.
$66
Kyowa Kirin, Inc.
$64
Foundation Medicine, Inc.
$57
Regeneron Healthcare Solutions, Inc.
$54
Lexicon Pharmaceuticals, Inc.
$45
TESARO, Inc.
$44
Acrotech Biopharma LLC
$40
Kite Pharma, Inc.
$36
Ipsen Biopharmaceuticals, Inc
$35
Dendreon Pharmaceuticals LLC
$34
Genentech, Inc.
$33
Genmab U.S., Inc.
$33
Biocon Biologics Inc
$32
MEDIVATION FIELD SOLUTIONS LLC
$31
Bayer Healthcare Pharmaceuticals Inc.
$28
APO-PHARMA USA, INC.
$27
JAZZ PHARMACEUTICALS INC.
$27
PharmaEssentia USA Corporation
$27
Myovant Sciences Inc.
$25
GlaxoSmithKline, LLC.
$25
Seattle Genetics, Inc.
$25
TAIHO ONCOLOGY, INC.
$23
Biocompatibles, Inc.
$23
Mirati Therapeutics, Inc.
$22
Spectrum Pharmaceuticals Inc.
$22
Alexion Pharmaceuticals, Inc.
$22
SpringWorks Therapeutics, Inc.
$22
Sumitomo Pharma America, Inc.
$21
Incyte Corporation
$20
INSYS Therapeutics Inc
$19
Azurity Pharmaceuticals, Inc.
$19
Boston Scientific Corporation
$18
Smith+Nephew, Inc.
$18
ImmunoGen, Inc.
$16
Teleflex LLC
$16
Advanced Accelerator Applications
$16
Taiho Oncology, Inc.
$15
Shire North American Group Inc
$15
Bard Peripheral Vascular, Inc.
$15
Karyopharm Therapeutics Inc.
$14
Clovis Oncology, Inc.
$12
Top 3 companies account for 48.3% of all-time payments
Associated products mentioned in payments ›
ADCETRIS · AFINITOR · ALIMTA · Abraxane · Alecensa · Aliqopa · Avastin · BELEODAQ · BESREMI · BOSULIF · BRAFTOVI · Balversa · Braftovi · CALQUENCE · CHANTIX · COLLAGENASE SANTYL · CYRAMZA · Columvi · DARZALEX · ELIQUIS · ELREXFIO · EMPLICITI · ENHERTU · ENROUTE Transcarotid Neuroprotection System · EPKINLY · ERLEADA · Elahere · Enhertu · Epkinly · Erleada · FERRIPROX · FOUNDATIONONE · FRUZAQLA · Fabhalta · Fulphila · GAZYVA · GILOTRIF · Halaven · IBRANCE · IMBRUVICA · IMFINZI · INFLECTRA · INLYTA · INTRAROSA · Imbruvica · Itovebi · JADENU · JAKAFI · JEMPERLI · KEYTRUDA · KISQALI · KRAZATI · Kadcyla · Kyprolis · LIBTAYO · LONSURF · LOQTORZI · LORBRENA · LUMAKRAS · LUTATHERA · LYNPARZA · Lenvima · Leqembi · Lonsurf · Lutathera · MANTA Vascular Closure Device · MEKINIST · MYLOTARG · MYRISK · NERLYNX · NINLARO · Nplate · Nubeqa · OGSIVEO · ONCASPAR · OPDIVO · OPDUALAG · ORGOVYX · OXBRYTA · Ocrevus · Oncology · Onivyde · Optune Lua (NovoTTF-200T) · PADCEV · POTELIGEO · PRECISETUMOR · PROMACTA · PROVENGE · Padcev · Phesgo · Pomalyst · Poteligeo · PreciseTumor · REBLOZYL · ROLVEDON · RYBREVANT · Revlimid · Rubraca · SARCLISA · SCEMBLIX · SIGNIA · SPACEOAR · SPRYCEL · SYNDROS · Stivarga · TAGRISSO · TASIGNA · TECENTRIQ · THERASPHERE-BIO · TIVDAK · ULTOMIRIS · Udenyca · VENCLEXTA · VERZENIO · VIVIMUSTA · VOTRIENT · Vitrakvi · Vyloy · XALKORI · XOSPATA · XPOVIO · XTANDI · Xermelo · Xtandi · Yescarta · ZEJULA · ZEPZELCA · ZYTIGA
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →
Most payments (63%) are for meals and travel — low-value interactions that are common across virtually all practicing physicians.
Geographic Context
Hematology & oncology specialists within 10 mi
103
Per 100K population
8.9
County median income
$125,727
Nearest hospital
JOHN MUIR MEDICAL CENTER - WALNUT CREEK CAMPUS
0.0 mi
0.0 mi
Data Sources
| Provider Registry | ✓ NPPES | Weekly updates |
| Medicare Enrollment | ✓ PECOS | Monthly updates |
| Practice Data | ✓ Medicare Util. | Annual (CY lag) |
| Industry Payments | ✓ Open Payments | CY 2024 |
| Disciplinary History | — Not public | N/A |
This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This reflects how much public data is available about a provider. How we calculate this →
Summary
Dr. Kang is a clinical cardiology specialist, with moderate Medicare volume, with low-engagement industry engagement, with 18 years of NPI registration.
This summary is auto-generated from federal data, describing data availability and patterns. Read our methodology →
Frequently Asked Questions
Is Dr. Kang experienced with office visit, established patient (30-39 min)?
Based on Medicare claims data, Dr. Kang performed 128 office visit, established patient (30-39 min) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Kang receive payments from pharmaceutical companies?
Yes. Dr. Kang received a total of $16,531 from 74 companies across 501 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Kang's costs compare to other hematology & oncology specialists in Walnut Creek?
Dr. Kang's average Medicare payment per service is $108. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Kang) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
Explore related providers
Same specialty & city
Hematology & Oncology Specialists in Walnut Creek
Browse hematology & oncology specialists in Walnut Creek ranked by procedure volume and transparency data.
Highest volume
Top Hematology & Oncology Specialists in CA
Hematology & oncology specialists ranked by total Medicare services performed statewide.
Industry payments
Pharma Payments to Hematology & Oncology Specialists in CA
Which CA hematology & oncology specialists receive the most from drug and device companies.
By company
E.R. Squibb & Sons, L.L.C. Payments to Doctors
See all physicians who received payments from E.R. Squibb & Sons, L.L.C.
By company
Novartis Pharmaceuticals Corporation Payments to Doctors
See all physicians who received payments from Novartis Pharmaceuticals Corporation.
By company
AstraZeneca Pharmaceuticals LP Payments to Doctors
See all physicians who received payments from AstraZeneca Pharmaceuticals LP.
About this page
All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.
This page is not medical advice, an endorsement, a recommendation, or a quality rating. Data Coverage reflects data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.
Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology